Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-37. (Canceled).

38. (Currently Amended) A method as in claim 54, wherein ~~for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:~~

~~implanting a vascular prosthesis in the blood vessel; and~~

~~releasing~~ methylprednisolone is released from the prosthesis at a rate between 5 μg/day to 200 μg/day.

39. (Previously Presented) A method as in claim 38, wherein methylprednisolone is released at a rate between 10 μg/day to 60 μg/day.

40. (Currently Amended) A method as in claim 54 ~~38~~, wherein methylprednisolone is released from the prosthesis within a time period of 1 day to 45 days in a vascular environment.

41. (Previously presented) A method as in claim 40, wherein methylprednisolone is released within a time period of 7 days to 21 days in a vascular environment.

42. (Currently Amended) A method as in claim 55 ~~38~~, further comprising releasing the at least one other substance simultaneously with methylprednisolone from the prosthesis.

43. (Currently Amended) A method as in claim 55 ~~38~~, further comprising releasing the at least one other substance sequentially with methylprednisolone from the prosthesis.

44. (Canceled).

45. (Currently Amended) A method as in claim 54 ~~38~~, wherein the releasing comprises delaying substantial release of methylprednisolone for at least one hour following implantation of the prosthesis.

46. (Previously Presented) A method as in claim 45, wherein delaying release comprises slowing releasing methylprednisolone from a reservoir with a material that at least partially degrades in a vascular environment over said one hour.

47. (Previously Presented) A method as in claim 45, wherein delaying release comprises slowing releasing methylprednisolone with a matrix that at least partially degrades in a vascular environment over said one hour.

48. (Previously Presented) A method as in claim 45, wherein delaying release comprises slowing releasing methylprednisolone with a nondegradable matrix that allows diffusion of methylprednisolone through the nondegradable matrix after said one hour.

49. (Previously Presented) A method as in claim 45, wherein delaying release comprises slowing releasing methylprednisolone with a rate limiting barrier that allows diffusion of methylprednisolone through the barrier after said one hour.

50. (Original) A method as in any one of claims 47-49, wherein the prosthesis is coated with the matrix or barrier by spraying, dipping, deposition, or painting.

51.-53. (Canceled).

54. (Previously Presented) A method for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:

implanting a vascular prosthesis in the blood vessel; and

releasing methylprednisolone and mycophenolic acid from the prosthesis when implanted in the blood vessel.

55. (Previously Presented) A method for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:

implanting a vascular prosthesis in the blood vessel; and

releasing methylprednisolone and at least one other substance in addition to methylprednisolone from the prosthesis when implanted in the blood vessel, wherein the at least one other substance comprises mizoribine.

56. (Currently Amended) A method as in claim 54 ~~38~~, ~~further comprising releasing at least one other substance in addition to methylprednisolone from the prosthesis when implanted in the blood vessel,~~ wherein methylprednisolone is substantially released within a time period of 2 days to 3 months.

57. (Canceled).

58. (Currently Amended) A method as in claim 54 ~~56~~, wherein methylprednisolone and mycophenolic acid ~~the at least one additional substance~~ are released simultaneously.

59. (Currently Amended) A method as in claim 54 ~~56~~, wherein methylprednisolone and mycophenolic acid ~~the at least one additional substance~~ are released sequentially.

60.-61. (Canceled)

62. (New) A method as in claim 55, wherein methylprednisolone is released from the prosthesis at a rate between 5 μg/day to 200 μg/day.

63. (New) A method as in claim 62, wherein methylprednisolone is released at a rate between 10 μg/day to 60 μg/day.

64. (New) A method as in claim 55, wherein methylprednisolone is released from the prosthesis within a time period of 1 day to 45 days in a vascular environment.

65. (New) A method as in claim 64, wherein methylprednisolone is released within a time period of 7 days to 21 days in a vascular environment.

66. (New) A method as in claim 55, wherein the releasing comprises delaying substantial release of methylprednisolone for at least one hour following implantation of the prosthesis.

67. (New) A method as in claim 66, wherein delaying release comprises slowing releasing methylprednisolone from a reservoir with a material that at least partially degrades in a vascular environment over said one hour.

68. (New) A method as in claim 66, wherein delaying release comprises slowing releasing methylprednisolone with a matrix that at least partially degrades in a vascular environment over said one hour.

69. (New) A method as in claim 66, wherein delaying release comprises slowing releasing methylprednisolone with a nondegradable matrix that allows diffusion of methylprednisolone through the nondegradable matrix after said one hour.

70. (New) A method as in claim 66, wherein delaying release comprises slowing releasing methylprednisolone with a rate limiting barrier that allows diffusion of methylprednisolone through the barrier after said one hour.

71. (New) A method as in any one of claims 68-70, wherein the prosthesis is coated with the matrix or barrier by spraying, dipping, deposition, or painting.

72. (New) A method as in claim 55, wherein methylprednisolone is substantially released within a time period of 2 days to 3 months.